Showing 3941-3950 of 9304 results for "".
- Analysis: Chronic Hand Eczema Affects 1 in 10 Adultshttps://practicaldermatology.com/news/chronic-hand-eczema-affects-1-in-10-adults-study-finds/2485383/A cross-sectional study of over 10,000 U.S. adults indicates chronic hand eczema (CHE) is more common than previously estimated, with nearly 1 in 10 reporting a physician diagnosis. The data, presented in a poster by Raj Chovati
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://practicaldermatology.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- Dr. Amy McMichael Highlights Breakthrough Alopecia Therapieshttps://practicaldermatology.com/news/dr-amy-mcmichael-highlights-breakthrough-alopecia-therapies/2485364/Anyone not using low-dose oral minoxidil yet has “missed the boat.” That was the message from Amy McMichael, MD, during her presentation on non-scarring hair loss at the 2026 Winter Clinical Dermatology Conference in Hawaii. Dr. McMichael, who before her presentation was named the conferen
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- TYK2 Inhibitor ICP-332 Demonstrates Efficacy, Safety in ADhttps://practicaldermatology.com/news/tyk2-inhibitor-icp-332-demonstrates-efficacy-safety-in-ad/2485331/A novel oral TYK2 inhibitor, ICP-332, demonstrated favorable safety and promising efficacy in a recent phase 2 randomized clinical trial for moderate to severe atopic dermatitis (AD). Researchers for the double-blind, placebo-co
- Analysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://practicaldermatology.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- Commentary Flags Risks in Minoxidil Use Among Older Adultshttps://practicaldermatology.com/news/commentary-flags-risks-in-minoxidil-use-among-older-adults/2485231/In a recent commentary published in the Journal of the American Academy of Dermatology, Funda Datli Yakaryilmaz, MD, and Dursun Turkmen, MD, raise concerns about safety monitoring for low-dose oral minoxidil (LDOM) in older